Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05532566 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Quercus Ilex and Quercus Robur Allergen Extracts Standardisation

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 1, 2025 (before its estimated November 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary and study completion dates: Nov 30, 2024 to Nov 30, 2025
    • Site details revised
    v3
  2. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Jan 31, 2024 to Nov 30, 2024
    • Study completion date: Apr 30, 2024 to Nov 30, 2024
    • Start date changed from estimate of Jan 2, 2023 to Jan 24, 2023
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The objective of this study is to determine the biological activity of Quercus illex and Quercus robur allergen extracts in histamine equivalent prick (HEP) units, in order to be used as in-house reference preparation (IHRP).
Trial Details
NCT Number NCT05532566
Lead Sponsor Inmunotek S.L.
Conditions
(from sponsor)		 Allergic Reaction, Allergic Skin Reaction, Allergy Pollen
Related terms Hypersensitivity, Rhinitis, Allergic, Seasonal
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov